Compare TR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | AGIO |
|---|---|---|
| Founded | 1896 | 2007 |
| Country | United States | United States |
| Employees | 2100 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | TR | AGIO |
|---|---|---|
| Price | $43.01 | $34.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.63 |
| AVG Volume (30 Days) | 117.9K | ★ 773.2K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $71.05 |
| Revenue Next Year | N/A | $163.65 |
| P/E Ratio | $32.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.13 | $22.24 |
| 52 Week High | $44.27 | $46.00 |
| Indicator | TR | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 76.02 |
| Support Level | $40.07 | $32.68 |
| Resistance Level | $43.37 | $43.72 |
| Average True Range (ATR) | 1.26 | 1.28 |
| MACD | 0.06 | 0.59 |
| Stochastic Oscillator | 75.14 | 74.81 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.